Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908327 | 0.94 | KDM1A (0.45) | KDM1AHTR7HTR2BHTR2AHCAR2 | |
| SCHEMBL11772061 | 0.77 | HTR2A (0.42) | KDM1AHTR2AHCAR2MAOBSIGMAR1 | |
| SCHEMBL5724727 | 0.77 | HDAC4 (0.41) | HTR7HTR2B | |
| SCHEMBL17014522 | 0.76 | SIGMAR1 (0.50) | KDM1ASIGMAR1AVPR1ATMEM97 | |
| SCHEMBL31683810 | 0.74 | AVPR1A (0.49) | KDM1AHTR2AHCAR2MAOBAVPR1A | |
| SCHEMBL10453624 | 0.74 | SLC6A3 (0.46) | HTR7HTR2B | |
| SCHEMBL1195856 | 0.74 | HTR7 (0.36) | KDM1AHTR7HTR2BSIGMAR1 | |
| SCHEMBL14706993 | 0.72 | MAPK1 (0.40) | KDM1AHCAR2MAOBSIGMAR1TMEM97 | |
| SCHEMBL1569110 | 0.71 | DPP4 (0.38) | HTR7HTR2BMAOB | |
| SCHEMBL15908336 | 0.70 | MAPK1 (0.42) | KDM1AHTR2AHCAR2MAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | KDM1A 2457/4885HTR7 1947/4885HTR2B 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.